United States· US:51662-1555_c3f1db01-58c0-2226-e053-2a95a90a8b33
HYALURONIDASE
A medicinal product containing hyaluronidase (human recombinant), registered in United States by HF Acquisition Co LLC, DBA HealthFirst.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- HYALURONIDASE (HUMAN RECOMBINANT)
- Manufacturer
- HF Acquisition Co LLC, DBA HealthFirst
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1151662155511 VIAL in 1 BOX (51662-1555-1) / 1 mL in 1 VIAL
- ndc1151662-1555-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf87e178-b370-4a2a-b8de-41e39d42b954 GET /v1/drugs/cf87e178-b370-4a2a-b8de-41e39d42b954?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "150",
"substance": "HYALURONIDASE (HUMAN RECOMBINANT)",
"productndc": "51662-1555",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "[USP'U]/mL",
"application_number": "BLA021859",
"marketing_category": "BLA"
}See everything about hyaluronidase (human recombinant).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.